Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Curis | CRIS | Jan 16, 2025 | 3.18 | -1.24 |
CURRENC Group | CURR | Jan 16, 2025 | 2.24 | +1.82 |
Curtiss-Wright | CW | Jan 16, 2025 | 365.91 | +1.12 |
Cushing Mlp & Infrastructure Total Return Fund | SRV | Jan 16, 2025 | 48.09 | +0.08 |
Cushman & Wakefield | CWK | Jan 16, 2025 | 13.14 | +1.86 |
Custom Truck One Source | CTOS | Jan 16, 2025 | 4.63 | -0.64 |
Customers Bancorp | CUBI | Jan 16, 2025 | 48.98 | -0.02 |
Customers Bancorp E Pref | CUBI-E | Jan 16, 2025 | 25.75 | -0.27 |
Customers Bancorp F Pref | CUBI-F | Jan 16, 2025 | 25.49 | -0.23 |
Cutera | CUTR | Jan 16, 2025 | 0.40 | -1.18 |
CVB Financial | CVBF | Jan 16, 2025 | 20.37 | -1.93 |
CVD Equipment | CVV | Jan 16, 2025 | 3.73 | -1.06 |
CVR Energy | CVI | Jan 16, 2025 | 21.62 | +1.74 |
Cvr Partners LP Unit | UAN | Jan 16, 2025 | 83.47 | +1.10 |
CVRx | CVRX | Jan 16, 2025 | 17.30 | +1.76 |
CVS Health | CVS | Jan 16, 2025 | 51.96 | -0.35 |
CXApp A | CXAI | Jan 16, 2025 | 1.89 | +3.85 |
CyberArk Software | CYBR | Jan 16, 2025 | 355.51 | +2.34 |
Cybin | CYBN | Jan 16, 2025 | 8.93 | -3.15 |
Cyclacel Pharmaceuticals | CYCC | Jan 16, 2025 | 0.35 | -3.50 |
Cyclacel Pharmaceuticals Pref | CYCCP | Jan 16, 2025 | 8.35 | +0.60 |
Cyclerion Therapeutics | CYCN | Jan 16, 2025 | 2.91 | -3.32 |
Cyclo Therapeutics | CYTH | Jan 16, 2025 | 0.78 | +4.20 |
Cyngn | CYN | Jan 16, 2025 | 0.61 | +0.74 |
Cytek Biosciences | CTKB | Jan 16, 2025 | 5.49 | -3.35 |
Cytokinetics | CYTK | Jan 16, 2025 | 46.99 | +0.26 |
Cytomed Therapeutics | GDTC | Jan 16, 2025 | 2.39 | +9.13 |
CytomX Therapeutics | CTMX | Jan 16, 2025 | 0.85 | -1.27 |
Cytosorbents | CTSO | Jan 16, 2025 | 1.04 | -3.70 |
D-MARKET Electronic Services & Trading ADR | HEPS | Jan 16, 2025 | 3.07 | -1.29 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.